12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Oral treprostinil regulatory update

FDA issued a complete response letter for a resubmitted NDA from United Therapeutics for oral treprostinil to treat pulmonary arterial hypertension (PAH). The company declined to disclose details of the letter, but said the agency did not raise any new...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >